Recombinant Human SMAD1 293 Cell Lysate

• Cat.No.: SMAD1-1678HCL

Specification

• Description: Antigen standard for SMAD family member 1 (SMAD1), transcript variant 1 is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
• Source: HEK 293 cells
• Species: Human
• Components: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
• Size: 0.1 mg
• Storage Instruction: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
• Applications: ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.
• Tag: Non

Gene Information

• Gene Name: SMAD1 SMAD family member 1 [ Homo sapiens ]
• Official Symbol: SMAD1
• Synonyms: SMAD1; SMAD family member 1; MAD, mothers against decapentaplegic homolog 1 (Drosophila) , MADH1, SMAD, mothers against DPP homolog 1 (Drosophila); mothers against decapentaplegic homolog 1; JV4 1; MADR1; MAD homolog 1; Mad-related protein 1; TGF-beta signaling protein 1; mothers against DPP homolog 1; SMAD, mothers against DPP homolog 1; MAD, mothers against decapentaplegic homolog 1; transforming growth factor-beta signaling protein 1; transforming growth factor-beta-signaling protein 1; BSP1; JV41; BSP-1; JV4-1; MADH1
• Gene ID: 4086
• mRNA Refseq: NM_005900
• Protein Refseq: NP_005891
• MIM: 601595
• UniProt ID: Q15797
• Chromosome Location: 4q31.21
• Pathway: ALK1 signaling events, organism-specific biosystem; ALK2 signaling events, organism-specific biosystem; BMP receptor signaling, organism-specific biosystem; Delta-Notch Signaling Pathway, organism-specific biosystem; ErbB1 downstream signaling, organism-specific biosystem; Heart Development, organism-specific biosystem; Id Signaling Pathway, organism-specific biosystem
• Function: I-SMAD binding; RNA polymerase II core promoter sequence-specific DNA binding; co-SMAD binding; identical protein binding; protein binding; protein kinase binding; receptor signaling protein activity; sequence-specific DNA binding transcription factor activity; transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity

Reviews

06/08/2022

Whether I am investigating enzymatic activity, studying protein-protein interactions, or testing its role in signaling pathways, the SMAD1 protein consistently performs exceptionally well.

08/08/2021

This versatility allows me to explore different aspects of my research with confidence and accuracy.

05/02/2018

The SMAD1 protein's excellent functionality makes it highly suitable for various trial applications.

Q&As

What technologies are commonly used to study the expression and activity of SMAD1 in clinical research?

Techniques like Western blotting, immunohistochemistry, and qRT-PCR are commonly employed to study SMAD1 expression and activity in clinical research.

How might targeting SMAD1 have implications for anti-cancer therapies?

Modulating SMAD1 activity could be explored as a potential strategy for developing anti-cancer therapies, particularly in cancers where the TGF-β pathway is dysregulated.

Are there any known genetic mutations in the SMAD1 gene associated with human diseases?

Yes, mutations in the SMAD1 gene have been identified in certain individuals with congenital disorders and developmental abnormalities.

How does SMAD1 interact with other proteins in the TGF-β pathway?

SMAD1 forms complexes with other SMAD proteins, transducing signals from TGF-β receptors to the nucleus, where they regulate gene expression.

How can SMAD1 be targeted for therapeutic interventions in bone-related disorders?

Targeting SMAD1 or its downstream effectors in the TGF-β pathway may offer potential therapeutic strategies for bone-related disorders, such as osteoporosis.